Akero Therapeutics Inc (AKRO)
19.94
-0.80
(-3.84%)
USD |
NASDAQ |
May 17, 16:00
19.94
0.00 (0.00%)
Pre-Market: 20:00
Akero Therapeutics Research and Development Expense (TTM): 170.66M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 170.66M |
| December 31, 2023 | 141.80M |
| September 30, 2023 | 106.73M |
| June 30, 2023 | 93.18M |
| March 31, 2023 | 86.56M |
| December 31, 2022 | 85.28M |
| September 30, 2022 | 94.68M |
| June 30, 2022 | 89.06M |
| March 31, 2022 | 91.67M |
| December 31, 2021 | 81.76M |
| September 30, 2021 | 79.76M |
| Date | Value |
|---|---|
| June 30, 2021 | 77.67M |
| March 31, 2021 | 66.73M |
| December 31, 2020 | 64.92M |
| September 30, 2020 | 52.34M |
| June 30, 2020 | 48.85M |
| March 31, 2020 | 41.77M |
| December 31, 2019 | 37.05M |
| September 30, 2019 | 25.89M |
| June 30, 2019 | 13.26M |
| March 31, 2019 | 15.72M |
| December 31, 2018 | 11.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
13.26M
Minimum
Jun 2019
170.66M
Maximum
Mar 2024
77.48M
Average
80.76M
Median
Research and Development Expense (TTM) Benchmarks
| 89bio Inc | 147.35M |
| Madrigal Pharmaceuticals Inc | 281.43M |
| Viking Therapeutics Inc | 76.90M |
| Ionis Pharmaceuticals Inc | 916.03M |
| Galectin Therapeutics Inc | 31.38M |